Clinical Study on the Heterogeneity Characteristics of Hepatobiliary Tumors and the Establishment of Individualized Treatment Strategies

This paper conducts a clinical study on personalized treatment based on tumor heterogeneity assessment. A total of 116 patients with liver and gallbladder tumors who visited the hepatobiliary surgery department of a public hospital from January 2022 to December 2024 were selected and randomly divided into a control group and an experimental group, with 58 cases in each group. Both groups received standard treatment; however, the experimental group, in addition to standard treatment, formulated personalized treatment strategies based on tumor heterogeneity assessment and molecular subtyping results. After three months of treatment, clinical indicators and efficacy were compared between the two groups. The experimental results showed that both groups improved clinically after treatment compared to before. Compared to the control group, the experimental group had a significantly lower rate of positive ROMs after three months of treatment. Moreover, stratified interventions based on heterogeneity characteristics demonstrated more significant improvements in treatment outcomes for patients with clonal target mutations, high tumor mutation burden, and portal vein cancer thrombi. Personalized treatment plans formulated based on tumor heterogeneity features can significantly improve symptoms, signs, and objective efficacy indicators in patients with liver and gallbladder tumors, providing new directions for optimizing clinical treatment strategies and offering potential for further promotion.